{"DataElement":{"publicId":"4572456","version":"1","preferredName":"Intervention or Procedure Discontinued Indicator","preferredDefinition":"A response for questions addressing the discontinuation of interventions and/or procedures.","longName":"INT_PROC_DISCON_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"4572453","version":"1","preferredName":"Intervention or Procedure Discontinued","preferredDefinition":"An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects._To stop or end, permanently or temporarily.","longName":"2233215v1.0:2433916v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2233215","version":"1","preferredName":"Procedure","preferredDefinition":"A particular course of action intended to achieve a result.","longName":"C25218","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intervention or Procedure","conceptCode":"C25218","definition":"An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9313AE8-B7EE-4260-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-12","modifiedBy":"ONEDATA","dateModified":"2005-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2433916","version":"1","preferredName":"Discontinued","preferredDefinition":"Discontinued; stopped permanently or temporarily.","longName":"C25484","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Discontinue","conceptCode":"C25484","definition":"To stop or end, permanently or temporarily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06674CCB-CDA9-04A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07103C5B-82B0-455B-E050-BB89AD431543","latestVersionIndicator":"Yes","beginDate":"2014-11-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-04","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"9/10/15 released. tt_9/8/15 edit to daft new DEC unused on 9525.tt_9525_Theradex_11.04.14_ghd_Protocol Pending.  To be released shortly.  07.13.15 ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"10000494","version":"1","longName":"Prior Treatments","context":"Theradex"}]},{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876424","version":"1","longName":"Prior Treatments","context":"Theradex"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"},{"name":"IE_IEORRES_CROS_DISCON","type":"OID, CCTG","context":"CCTG"}],"ReferenceDocuments":[{"name":"Were the interventions or pro","type":"Preferred Question Text","description":"Were the interventions or procedures discontinued accordingly?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"If patient has received hydroxyurea or glucocorticoids for suppression of leukocytosis, have these agents been discontinued at least 24 hours prior to initiation of therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"If patient is enrolled on Phase I portion, has prior EGFR-TKIs (except erlotinib) been discontinued at least 7 days prior to initiation of erlotinib and Onalespib?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"If patient requires treatment with a RANKL inhibitor (e.g. denosumab) can it be discontinued before treatment with atezolizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"If patient requires treatment with a RANKL inhibitor (e.g. denosumab), is patient able to discontinue it before treatment with atezolizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Does patient require treatment with a RANKL inhibitor (e.g. denosumab) which cannot be discontinued before treatment with atezolizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"If patient is on chronic anticoagulation treatment, is patient able and willing to have this treatment discontinued for the biopsy?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Has patient been off other anti-cancer therapy, including ACT, for 28 days prior to study administration of atexolizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"If patient is receiving hydroxyurea, has it been discontinued on the day prior to the start of chemotherapy?Â ","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Does treating physician agree to suspend cancer chemotherapy for patients in cancer remission during tocilizumab treatment phase until the patient improves to Clinical Ordinal Scale of 1 or 2?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"If patient is on long-acting somatostatin analogs (e.g., long-acting octreotide) can it be discontinued at least 4 weeks prior to initiating Lutetium Lu 177 Dotatate or will it be continued for patient who has a history of carcinoid syndrome and requires long-acting somatostatin analog for control of his/her functional syndrome?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"If patient is on chronic anticoagulation treatment, is patient unable and unwilling to have this treatment discontinued for the biopsy?","url":null,"context":"Theradex"},{"name":"COG CRF Text 01","type":"Alternate Question Text","description":"Did the patient not proceed to cycle 6 due to discontinuation of Isotretinoin?","url":null,"context":"COG"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Is patient on chronic anticoagulation treatment, that cannot be discontinued during the time interval necessary to undergo a biopsy?","url":null,"context":"Theradex"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Was study drug administration discontinued during this reporting period?","url":null,"context":"COG"},{"name":"Did the patient discontinue chemotherapy for non-malignant conditions prior to starting protocol therapy?","type":"Alternate Question Text","description":"Did the patient discontinue chemotherapy for non-malignant conditions prior to starting protocol therapy?","url":null,"context":"COG"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"If patient received prior treatment with anti-PD-1/PD-L1 inhibitors or anti CTLA4 antibodies, were they permanently discontinued from further treatment because of an adverse event?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Has patient been off cytotoxic chemotherapy, immunotherapy, major surgery (other than diagnostic surgery, dental surgery or stenting), or other investigational therapy more than 3 weeks prior to entering the study?","url":null,"context":"Theradex"},{"name":"CCTG_01","type":"Alternate Question Text","description":"Permanent discontinuation of everolimus","url":null,"context":"CCTG"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Did the patient meet any criteria that resulted in permanent discontinuation of study treatment during induction treatment phase, as outlined in section 5.4.","url":null,"context":"NRG"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07103C5B-8434-455B-E050-BB89AD431543","latestVersionIndicator":"Yes","beginDate":"2014-11-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-04","modifiedBy":"TSESU","dateModified":"2023-03-27","changeDescription":"9/10/15 released.tt_9/8/15 edit to draft new CDE unused on 9525. tt_9525_Theradex_11.04.14_ghd","administrativeNotes":"3/7/23 added 1 alt OID and 1 AQT for CCTG ticket request CADSR0002117 cjl.","unresolvedIssues":null,"deletedIndicator":"No"}}